Final Report on Real World Effectiveness of Sequential Afatinib and Osimertinib in EGFR Positive Advanced Non-small Cell Lung Cancer

被引：0
|
作者：
Jang, T. W. [1 ]
Kim, T. [2 ]
机构：
[1] Kosin Univ Gospel Hosp, Busan, South Korea
[2] Armed Forces Goyang Hosp, Goyang, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Afatinib; osimertinib; real-world effectiveness;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-27
引用
收藏
页码：S651 / S651
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer
    Bertranou, Evelina
    Bodnar, Carolyn
    Dansk, Viktor
    Greystoke, Alastair
    Large, Samuel
    Dyer, Matthew
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (02) : 113 - 121
  • [32] Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China
    Cai, Hongfu
    Zhang, Longfeng
    Li, Na
    Chen, Shen
    Zheng, Bin
    Yang, Jing
    Weng, Lizhu
    Liu, Mao-Bai
    CLINICAL THERAPEUTICS, 2019, 41 (02) : 280 - 290
  • [33] Real-World Multicenter Experience of First-line Afatinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer
    Liam, C. K.
    Chai, C.
    Ho, G.
    Alip, A.
    Wahid, M. I. A.
    Abdullah, M. M.
    Foo, Y. C.
    How, S. H.
    Zaatar, A.
    Lam, K. S.
    Leong, K. W.
    Low, J. S. H.
    Yusof, M. Md
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S848 - S848
  • [34] Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
    van Veggel, B.
    Santos, J. F. Vilacha Madeira R.
    Hashemi, S. M. S.
    Paats, M. S.
    Monkhorst, K.
    Heideman, D. A. M.
    Groves, M.
    Radonic, T.
    Smit, E. F.
    Schuuring, E.
    van der Wekken, A. J.
    de Langen, A. J.
    LUNG CANCER, 2020, 141 : 9 - 13
  • [35] First-line Afatinib for Non-Small Cell Lung Cancer in Real World Practice
    Kim, Y.
    Sun, J.
    Park, K.
    Park, S. E.
    Lee, S.
    Ahn, M.
    Ahn, J. S.
    Lim, S. W.
    Lee, H.
    Cho, J. H.
    Kim, H. K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2209 - S2209
  • [36] Early dose reduction of osimertinib in advanced EGFR-mutated non-small cell lung cancer
    Ferreira, Marion
    Ebia, Matthew I.
    Reckamp, Karen L.
    ANTI-CANCER DRUGS, 2024, 35 (07) : 672 - 679
  • [37] Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancer
    Spagnuolo, Alessia
    Gridelli, Cesare
    EXPERT OPINION ON PHARMACOTHERAPY, 2025, : 491 - 501
  • [38] Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)
    Sakata, Yoshihiko
    Saito, Go
    Sakata, Shinya
    Oya, Yuko
    Tamiya, Motohiro
    Suzuki, Hidekazu
    Shibaki, Ryota
    Okada, Asuka
    Yokoyama, Toshihide
    Matsumoto, Hirotaka
    Otsuki, Taiichiro
    Sato, Yuki
    Junji, Uchida
    Tsukita, Yoko
    Inaba, Megumi
    Ikeda, Hideki
    Arai, Daisuke
    Maruyama, Hirotaka
    Hara, Satoshi
    Tsumura, Shinsuke
    Morinaga, Jun
    Sakagami, Takuro
    LUNG CANCER, 2023, 186
  • [39] Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies
    Miura, Satoru
    Jung, Hyun Ae
    Lee, Shin Yup
    Lee, Seung Hyeun
    Lee, Min Ki
    Lee, Yong Chul
    Hochmair, Maximilian J.
    Yang, Cheng-Ta
    Marten, Angela
    Yang, James Chih-Hsin
    Popat, Sanjay
    ONCOTARGETS AND THERAPY, 2022, 15 : 873 - 882
  • [40] Safety of osimertinib in EGFR-mutated non-small cell lung cancer
    Mezquita, Laura
    Varga, Andreea
    Planchard, David
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1239 - 1248
12345